Merck (MRK) said Friday it has received approval for Welireg from China's National Medical Products Administration to treat adults with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.
The approval was based on the results of a phase 2 study, Merck said.
Welireg, or belzutifan, is approved in the US for the same indication as well as for previously treated advanced renal cell carcinoma, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments